# Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis

> **NCT03265613** · PHASE1,PHASE2 · COMPLETED · sponsor: **Guangdong Provincial Hospital of Traditional Chinese Medicine** · enrollment: 7 (actual)

## Conditions studied

- Mesenchymal Stromal Cells
- Psoriasis
- Drug Toxicity
- Drug Effect

## Interventions

- **BIOLOGICAL:** adipose-derived multipotent mesenchymal stem cells

## Key facts

- **NCT ID:** NCT03265613
- **Lead sponsor:** Guangdong Provincial Hospital of Traditional Chinese Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-24
- **Primary completion:** 2019-08-20
- **Final completion:** 2019-11-28
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2023-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03265613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03265613, "Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03265613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*